14Indexed trials
drug · Product Intelligence
Ketamine
Pipeline Intelligence
Ketamine: 14 indexed trials, 14 sponsors; 0 linked Orange Book patents and 8 FDA-linked events where matched.
14Sponsors
0Orange Book patent links
8FDA-linked events
Development evidence
NCT01126957University of Missouri-Columbia · other_neurologyNA
NCT01260649Massachusetts General Hospital · depressionPHASE4
NCT02267980Inonu University · depressionPHASE4
NCT02579928Yale University · depressionPHASE4
NCT02593643Sunnybrook Health Sciences Centre · depressionEARLY_PHASE1
NCT02636218Unity Health Toronto · other_neurologyPHASE2, PHASE3
NCT02836288Scott A. Irwin, MD, PhD · depressionEARLY_PHASE1
NCT03475277Stanford University · other_neurologyCOMPLETED
NCT03609190Psychiatric University Hospital, Zurich · depressionEARLY_PHASE1
NCT03814733Naurex, Inc, an affiliate of Allergan plc · out_of_scopePHASE1
NCT04283058Loma Linda University · depressionWITHDRAWN
NCT05320991University Hospital, Bonn · schizophreniaPHASE4
NCT05756621University of Milano Bicocca · epilepsyCOMPLETED
NCT06038409RIVER Foundation · depressionRECRUITING
FDA / patent evidence
Orange Book match found; no listed patent relation was retained for this product match.
Regulatory context
FDA_APPROVALKETAMINE HYDROCHLORIDE · 2026-08-11
FDA_APPROVALKETAMINE HYDROCHLORIDE · 2025-08-07
FDA_APPROVALKETAMINE HYDROCHLORIDE · 2023-01-24
FDA_APPROVALKETAMINE HYDROCHLORIDE · 2023-01-13
FDA_APPROVALKETAMINE HYDROCHLORIDE · 2001-12-28
FDA_APPROVALKETAMINE HYDROCHLORIDE · 1996-06-27
FDA_APPROVALKETAMINE HYDROCHLORIDE · 1996-03-22
FDA_APPROVALKETALAR ·
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.